Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

August 1, 2018

Study Completion Date

September 30, 2018

Conditions
End-stage Renal DiseaseHCV Coinfection
Interventions
DRUG

Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet

"* Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."

Trial Locations (1)

71515

Assiut University Hopsital, Asyut

All Listed Sponsors
collaborator

Sohag University

OTHER

collaborator

South Valley University

OTHER

lead

Assiut University

OTHER

NCT03499639 - Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease | Biotech Hunter | Biotech Hunter